Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?

Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.